美国根治性膀胱切除术费用差异研究
该队列研究纳入2003至2015年美国208家医院的23173例因膀胱癌行根治性膀胱切除术患者,评估90天直接医院费用的变异及预测因素。平均费用为39651美元,术后并发症对费用变异贡献最大(84.5%),其次为患者因素(49.8%)和手术因素(33.2%)。
要点
- 平均90天直接医院费用为39651美元,其中指数住院占87.8%。
- 术后并发症对费用变异贡献最大(84.5%),其次为患者因素(49.8%)。
- 发生非致命主要并发症(OR 12.7)和死亡(OR 13.5)与高费用显著相关。
核心结论
- 术后并发症、患者合并症和手术年份对费用变异贡献最大,而医院和手术相关特征如手术量、机器人辅助和尿流改道类型对极端费用贡献较小。
研究设计与样本
- 队列研究,纳入2003至2015年美国208家医院23173例因膀胱癌行根治性膀胱切除术的患者,数据来自Premier Healthcare Database。
主要发现
- 每次根治性膀胱切除术的平均90天直接医院费用为39651美元(标准差34427美元),其中指数住院占87.8%(34803美元),出院后再入院占12.2%(4847美元)。
- 术后并发症对费用变异贡献最大(84.5%),其次为患者因素(49.8%;例如Charlson合并症指数[CCI]贡献40.5%)、手术因素(33.2%;例如手术年份贡献25.0%)和医院特征(8.0%)。
- 发生轻微并发症(OR 2.63,95%CI 2.03-3.40)、非致命主要并发症(OR 12.7,95%CI 9.63-16.8)和死亡(OR 13.5,95%CI 9.35-19.4,均p<0.001)与高费用显著相关。
- 病情更重的患者(CCI=2:OR 0.41,95%CI 0.29-0.59;CCI=1:OR 0.58,95%CI 0.46-0.75,均p<0.001)、接受可控性尿流改道者(相比不可控性尿流改道:OR 0.29,95%CI 0.16-0.53,p<0.001)和较早手术时期与低费用呈负相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radical cystectomy (RC) for muscle-invasive bladder cancer (BCa) has potential for serious complications, prolonged length of stay and readmissions-all of which may increase costs. Although variations in outcomes are well described, less is known about determinants driving variation in costs. OBJECTIVE: To assess surgeon- and hospital-level variations in costs and predictors of high- and low-cost RC. DESIGN, SETTING, AND PARTICIPANTS: Cohort study of 23 173 patients who underwent RC for BCa in 208 hospitals in the USA from 2003 to 2015 in the Premier Healthcare Database. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Ninety-day direct hospital costs; multilevel hierarchal linear models were constructed to evaluate contributions of each variable to costs. RESULTS AND LIMITATIONS: Mean 90-d direct hospital costs per RC was $39 651 (standard deviation $34 427), of which index hospitalization accounted for 87.8% ($34 803) and postdischarge readmission(s) accounted for 12.2% ($4847). Postoperative complications contributed most to cost variations (84.5%), followed by patient (49.8%; eg, Charlson Comorbidity Index [CCI], 40.5%), surgical (33.2%; eg, year of surgery [25.0%]), and hospital characteristics (8.0%). Patients who suffered minor complications (odds ratio [OR] 2.63, 95% confidence interval [CI]: 2.03-3.40), nonfatal major complications (OR 12.7, 95% CI: 9.63-16.8), and mortality (OR 13.5, 95% CI: 9.35-19.4, all p<0.001) were significantly associated with high costs. As for low-cost surgery, sicker patients (CCI=2: OR 0.41, 95% CI: 0.29-0.59; CCI=1: OR 0.58, 95% CI: 0.46-0.75, both p<0.001), those who underwent continent diversion (vs incontinent diversion: OR 0.29, 95% CI: 0.16-0.53, p<0.001), and earlier period of surgery were inversely associated with low costs. CONCLUSIONS: This study provides insight into the determinants of costs for RC. Postoperative morbidity, patient comorbidities, and year of surgery contributed most to observed variations in costs, while other hospital- and surgical-related characteristics such as volume, use of robot assistance, and type of urinary diversion contribute less to outlier costs. PATIENT SUMMARY: Efforts to address high surgical cost must be tailored to specific determinants of high and low costs for each operation. In contrast to robot-assisted radical prostatectomy where surgeon factors predominate, high costs in radical cystectomy were primarily determined by postoperative complication and patient comorbidities.
引用
- Leow JJ, Cole AP, Seisen T, et al. Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. Eur Urol. 2017. PMID: 28803034. doi:10.1016/j.eururo.2017.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。